Profits, pressure, and perception: Expensive research collides with medicine

Journal of Rheumatology

Volumn 30, Issue 8, 2003, Pages 1661-1662

  Hoey, John ^a  

^a CMAJ   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CONTINUING EDUCATION; ECONOMIC ASPECT; EDITORIAL; FINANCIAL MANAGEMENT; POLICY; PRIORITY JOURNAL; PROFIT; PUBLICATION; REGULATORY MECHANISM;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

CONFLICT OF INTEREST; DRUG INDUSTRY; PEER REVIEW, RESEARCH; RESEARCH SUPPORT; SCIENTIFIC MISCONDUCT;

EID: 0043031388     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (22)

1. Gordon DA. Medical publication ethics [editorial]. J Rheumatol 2003;30:1851-6.
2. Questions of interest [editorial]. CMAJ 2002;166:413.
3. Baird P. Getting it right: industry sponsorship and medical research. CMAJ 2003;168:1267-9.
4. Kettler H. Updating the cost of a new chemical entity. London: Office of Health Economics; 1999. Summary available from: http://www.ohe.org/updating.htm#Updating [accessed April 15, 2003].
5. Davidoff F, DeAngelis CD, Drazen JM, et al. Sponsorship, authorship and accountability. CMAJ 2001;165:786-8.
6. Look, no strings: publishing industry-funded research [editorial]. CMAJ 2001;165:733.
7. Drug marketing: Unsafe at any dose? [editorial]. CMAJ 2002;167:981.
8. Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ 2001;164:1612.
9. University of Pennsylvania. Financial disclosure and forbidden conflicts for faculty participating in clinical trials [accessed April 17, 2003]. Available from: http://www.upenn.edu/research/financialdisclosure_clinicaltrials.htm
10. Phillips RA, Hoey J. Constraints of interest: lessons at the Hospital for Sick Children. CMAJ 1998;159:955-7.
11. Naylor CD, for the Research Committee and Clinical Study Agreements Working Group of the Toronto Academic Health Science Council. Early Toronto experience with new standards for industry-sponsored clinical research: a progress report [editorial]. CMAJ 2002;166:453-6.
12. Naylor CD. Early Toronto experience with new standards for industry-sponsored clinical research: a progress report. CMAJ 2002;166:453-6.
13. Lewis S, Baird P, Evans RG, et al. Dancing with the porcupine: rules for governing the university-industry relationship. CMAJ 2001;165:783-5.
14. Yeo M. Marketing R&D: one step forward, two steps back. CMAJ 2003;168:1273-4.
15. Hansen D. CMAJ 2003;168 [in press]
16. Yeo M. CMAJ 2003;168 [in press]
17. Hadler NM. Options in disability determination. Lessons that pertain to the regional musculoskeletal disorders. J Rheumatol 2002;29:407-10.
18. Panush RS. Not for sale, not even for rent: just say no. Thoughts about the American College of Rheumatology adopting a code of ethics. J Rheumatol 2002;29:1049-57.
19. Laxer RM, Harrison C. Bioethical issues in autologous stem cell transplantation in children and adults with arthritis. J Rheumatol 2001;28:2147-50.
20. Harrison C, Laxer RM. A bioethics education program in pediatric rheumatology. J Rheumatol 2000;27:1780-2.
21. Gordon DA. Rheumatoid arthritis - new treatments, and a new look at medical ethics. J Rheumatol 1998;25:2049.
22. Levine RJ. Postmarketing surveillance - some ethical considerations. J Rheumatol 1988;15 Suppl 17:34-9.